Notice NOT-AG-19-029 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-20-007 from the NIH Guide for Grants and Contracts. The primary focus of this FOA is to promote studies which apply state-of-the art concepts, technologies, and methodologies in the stem cell field to better understand how stem cells function within diseased or damaged gynecologic tissues. For the purposes of this announcement, the gynecologic disorders of interest are limited to uterine fibroids, endometriosis, adenomyosis, endometrial polyps, and pelvic organ prolapse. These disorders have been chosen based on their prevalence, high associated morbidity, high branch priority, and substantial costs to the healthcare system. The ultimate goal of this initiative is to improve womens gynecologic health by accelerating our understanding of the role of pluripotent progenitor/stem cells in the initiation, progression and severity of these gynecologic disorders in order to inform the development of effective prevention, diagnostic, and therapeutic strategies.

Notice NOT-OD-19-122 from the NIH Guide for Grants and Contracts

Notice NOT-OD-19-127 from the NIH Guide for Grants and Contracts

Notice NOT-RM-19-013 from the NIH Guide for Grants and Contracts

Notice NOT-AI-19-064 from the NIH Guide for Grants and Contracts

Notice NOT-GM-19-048 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-325 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Notice NOT-GM-19-054 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-021 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-19-319 from the NIH Guide for Grants and Contracts. The NIDDK Central Repositories house valuable biological samples and data from numerous major clinical studies. This initiative allows investigators to apply for access to non-renewable samples from one or more of these studies. Information about the samples available can be found at https://repository.niddk.nih.gov. Applicants must provide a report from the NIDDK Central Repositories documenting sample availability.

Notice NOT-AG-19-035 from the NIH Guide for Grants and Contracts

Notice NOT-AG-19-032 from the NIH Guide for Grants and Contracts

Notice NOT-AG-19-034 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-080 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-19-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests applications for Polycystic Kidney Disease (PKD) Research and Translation Core Centers (RTCC). The RTCCs are expected to work collaboratively with the Central Coordinating Site (CCS) as part of a PKD Research Consortium and serve as a national resource for the larger research community. The RTCCs should develop and share research resources (e.g. reagents, tools etc.), services and expertise that would be difficult or impractical to support in individual labs. The FOA is open to new applications, not renewals. Previously funded PKD Centers may apply as new centers.

Funding Opportunity RFA-DK-19-011 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests applications for the Central Coordinating Site (CCS) for the Polycystic Kidney Disease (PKD) Research and Translation Core Centers (RTCC). The CCS is expected to work collaboratively with four RTCCs as part of the PKD Research Consortium and serve as a national resource for the larger research community. The CCS will provide central administrative and communications support for the Consortium. All activities within the Consortium are expected to address the overall goal of improving our understanding of the pathogenesis, progression, prevention and clinical management of PKD through enhanced sharing of resources and establishment of a robust research community. This FOA is a companion announcement to RFA-DK-19-010:Polycystic Kidney Disease Research and Translation Core Centers (U54).

Notice NOT-OD-19-128 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-063 from the NIH Guide for Grants and Contracts

Notice NOT-DK-19-020 from the NIH Guide for Grants and Contracts